USFDA gives 5 observations to Glenmark Pharma for Goa facility

The company is committed to undertake all necessary steps required to address their observations at the earliest.

653
USFDA
Picture: Pixabay

Last Updated on May 25, 2022 by The Health Master

Mumbai: Drugmaker, Glenmark Pharma, has recently announced that the US Food and Drug Administration (USFDA) has issued Form 483 with five observations after an inspection at the Company’s formulation manufacturing facility based out of Goa, India.

The inspection was conducted between May 12, 2022 and May 20, 2022.”This is to inform you that the USFDA has issued Form 483 with five observations after an inspection at the Company’s formulation manufacturing facility based out of Goa, India between May 12, 2022 and May 20, 2022,” the company stated in a BSE filing.

An FDA Form 483 is issued to firm management at the conclusion of an inspection when an investigator(s) has observed any conditions that in their judgment may constitute violations of the Food Drug and Cosmetic (FD&C) Act and related Acts.

“The company is committed to undertake all necessary steps required to address their observations at the earliest.

The Company is committed to maintaining the highest quality manufacturing standards at all of its facilities across the globe,” Glenmark added.

Glenmark Pharmaceuticals Limited is a global research-led pharmaceutical company with presence across generics, specialty and OTC businesses and with operations in over 50 countries.

Glenmark’s key therapy focus areas globally are respiratory, dermatology and oncology.

USFDA gives 10 observations to Sun Pharm

USFDA gives Zero Observations to SMS Lifesciences

USFDA issues 4 Observations to Lupin for Tarapur Facility

USFDA gives 13 observations to Lupin

USFDA complete audit of Granules Pharmaceuticals with 3 observations

USFDA issues 3 observations on Zydus manufacturing unit

De-addiction center raided by joint team of FDA Haryana & Police: HM

Drug recall: Over 10,000 bottles of generic Anti-depression Drug recalled

Financial aid to the family of late Sh. Sudip Ganguly, Drug Inspector West Bengal

Govt adds psoriasis drug Acitretin under Schedule H of Drugs Rules

NPPA has launched an exercise to cap the huge margins of medicines

FDA lodged FIR for manufacturing BP monitoring machines without license

USFDA gives nod to Glenmark for Abiraterone Acetate tablets USP 500 mg

Govt amends Rules to add suspension and cancellation of license provisions…

FAQs – on Schedule-P (Expiry Date of drugs)

Latest Notifications regarding Pharmaceuticals

For informative videos on the news regarding Pharma / Medical Devices / Cosmetics / Homoeopathy etc., click on the below YouTube icon:

YouTube Icon

For informative videos by The Health Master, click on the below YouTube icon:

YouTube Icon
Telegram
WhatsApp
Facebook
LinkedIn
YouTube Icon
Google-news

Enter your email address:

Delivered by FeedBurner